Astrana Health (ASTH) drew fresh attention after updating its investor presentation at the 44th Annual J.P. Morgan Healthcare Conference, outlining its delegated risk and care delivery model across 16 markets and its evolution into a national platform.
See our latest analysis for Astrana Health.
The refreshed presentation coincides with a recent 15.55% 1 month share price return. However, the 1 year total shareholder return of a 13.05% decline and 3 year total shareholder return of a 22.73% decline suggest longer term momentum has been weaker, even as Astrana outlines its broader national ambitions.
If Astrana’s move toward a national platform has caught your attention, it could be a useful moment to compare it with other healthcare stocks that are shaping the sector.
With Astrana trading at US$27.12 and sitting at a discount to analyst targets and an indicated intrinsic value, the key question is whether this gap reflects an undervalued national platform in progress or a market that is already pricing in future growth.
With Astrana Health last closing at US$27.12 against a narrative fair value of US$40.25, the gap between price and implied worth is clear and sets the scene for a closer look at what is driving that view.
Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention, positioning Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages. This likely supports both revenue growth and sustainable margin expansion over time.
Read the complete narrative.
Curious what kind of revenue mix, margin profile, and earnings power sit behind that fair value and discount rate of 7.33%? The narrative leans on a full risk model, scaled revenue expectations, and a future earnings multiple that needs to compress from today’s level. Want to see how those moving parts fit together into a single valuation story?
Result: Fair Value of $40.25 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that story can break if full risk contract conversions stumble, or if reimbursement shifts across Medicare Advantage and Medicaid squeeze already thin margins.
Find out about the key risks to this Astrana Health narrative.
That 32.6% narrative discount and the SWS fair value of US$40.25 lean on future cash flows, but the current P/E of 142.6x tells a very different story. It sits well above the Healthcare industry at 23.3x and the fair ratio of 26.4x, which points to meaningful valuation risk if expectations reset.
Put simply, cash flow based models see room in the price. By contrast, the earnings multiple looks stretched versus both peers and where the fair ratio suggests the P/E could drift. Which lens do you think better fits Astrana’s mix of thin margins, forecast profit growth, and execution risk?
See what the numbers say about this price — find out in our valuation breakdown.
If parts of this story do not sit right with you, or you would rather test the numbers yourself, you can build a fresh view in just a few minutes, Do it your way.
A great starting point for your Astrana Health research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
If Astrana is on your radar, that is a good start. However, you may miss other themes that could suit your style if you stop there.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASTH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
link